When given concurrently with chemoradiotherapy, AstraZeneca’s Imfinzi in a late-stage lung cancer study did not lead to significant improvements in progression-free survival versus chemoradiotherapy alone.
Tag Archive for: durvalumab)
Thursday, AstraZeneca reported data from the Phase III ADAURA trial showing its Tagrisso (osimertinib) boosts overall survival (OS) as an adjuvant treatment for early non-small cell lung cancer (NSCLC) after curative resection.
The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) and platinum-based chemotherapy Thursday for adult patients with metastatic non-small cell lung cancer (NSCLC).
AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States, the company announced during its third-quarter report. It is also abandoning three early-stage programs.
The FDA approved AstraZeneca’s Imfinzi (durvalumab) plus with gemcitabine-cisplatin chemotherapy as the first immunotherapy for adult patients with locally advanced or metastatic biliary tract cancer.
